相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
Nynke G. L. Jager et al.
BMC CANCER (2013)
CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
Wendy A. Teft et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
Matthew P. Goetz et al.
CLINICAL CANCER RESEARCH (2013)
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
Laure Elens et al.
PHARMACOGENOMICS (2013)
Clinical and biomarker predictors of side effects from tamoxifen
Wendy Lorizio et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
I. Sestak et al.
BRITISH JOURNAL OF CANCER (2012)
Effects of CYP Induction by Rifampicin on Tamoxifen Exposure
L. Binkhorst et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Pharmacogenetics of Endocrine Therapy for Breast Cancer
Michaela J. Higgins et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Effects of Baicalein on the Pharmacokinetics of Tamoxifen and its Main Metabolite, 4-Hydroxytamoxifen, in Rats: Possible Role of Cytochrome P450 3A4 and P-glycoprotein inhibition by Baicalein
Cheng Li et al.
ARCHIVES OF PHARMACAL RESEARCH (2011)
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
T. E. Muerdter et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
L. Madlensky et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
William J. Irvin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Effect of hormone metabolism genotypes on steroid hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition
Timothy R. Rebbeck et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2010)
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
N. Lynn Henry et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Menopausal hot flushes revisited
M. Andrikoula et al.
CLIMACTERIC (2009)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Tamoxifen, hot flashes and recurrence in breast cancer
Joanne E. Mortimer et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial
Jack Cuzick et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes:: Data from the Italian tamoxifen trial
Bernardo Bonanni et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Cytochrome P450-mediated metabolism of estrogens and its regulation in human
Y Tsuchiya et al.
CANCER LETTERS (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen
YC Lim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer
L Gallicchio et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
分享论文
